journal article·2021-07Open access

Combining Photothermal‐Photodynamic Therapy Mediated by Nanomaterials with Immune Checkpoint Blockade for Metastatic Cancer Treatment and Creation of Immune Memory

Rita Lima‐Sousa, Bruna L. Melo, Cátia G. Alves, André F. Moreira, António G. Mendonça, Ilídio J. Correia, Duarte de Melo‐Diogo

Advanced Functional Materials· Volume 31· Issue 29

Abstract

Abstract The pursuit of effective treatments for metastatic cancer is still one of the most intensive areas of research in the biomedical field. In a not‐so‐distant past, the scientific community has witnessed the rise of immunotherapy based on immune checkpoint inhibitors (ICIs). This therapeutic modality intends to abolish immunosuppressive interactions, re‐establishing T cell responses against metastasized cancer cells. Despite the initial enthusiasm, the ICIs were later found to be associated with low clinical therapeutic outcomes and immune‐related side effects. To address these limitations, researchers are exploring the combination of ICIs with nanomaterial‐mediated phototherapies. These nanomaterials can accumulate within the tumor and produce, upon interaction with light, a temperature increase (photothermal therapy) and/or reactive oxygen species (photodynamic therapy), causing damage to cancer cells. Importantly, these photothermal‐photodynamic effects can pave the way for an enhanced ICI‐based immunotherapy by inducing the release of tumor‐associated antigens and danger‐associated molecular patterns, as well as by relieving tumor hypoxia and triggering a pro‐inflammatory response. This progress report analyses the potential of nanomaterial‐mediated photothermal‐photodynamic therapy in combination with ICIs, focusing on their ability to modulate T cell populations leading to an anti‐metastatic abscopal effect and on their capacity to generate immune memory that prevents tumor recurrence.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CICS‐UBI—Centro de Investigação em Ciências da Saúde Universidade da Beira Interior Covilhã 6200‐506 Portugal

Departamento de Química Universidade da Beira Interior Covilhã 6201‐001 Portugal

CIEPQPF—Departamento de Engenharia Química Universidade de Coimbra Coimbra 3030‐790 Portugal

Funding

European Regional Development Fund · Fundação para a Ciência e a Tecnologia

References (100+)

Show source-provided references
1. 10.1016/j.apsb.2015.07.00510.1016/j.apsb.2015.07.005 ↗
2. 10.1007/s00018-016-2210-510.1007/s00018-016-2210-5 ↗
3. 10.1634/theoncologist.2017-064810.1634/theoncologist.2017-0648 ↗
4. 10.1038/s41467-019-11730-810.1038/s41467-019-11730-8 ↗
5. 10.1021/acsnano.7b0473610.1021/acsnano.7b04736 ↗
6. 10.1089/jir.2018.001910.1089/jir.2018.0019 ↗
7. 10.1038/s41577-020-0306-510.1038/s41577-020-0306-5 ↗
8. 10.1016/j.jconrel.2018.10.00810.1016/j.jconrel.2018.10.008 ↗
9. Webb E. S. · J. Biomed. Res. · 2018 · 32 · 31710.7555/JBR.31.20160168 ↗
10. 10.3390/cancers1203073810.3390/cancers12030738 ↗
11. 10.1016/j.intimp.2018.06.00110.1016/j.intimp.2018.06.001 ↗
12. 10.1038/s41467-020-17670-y10.1038/s41467-020-17670-y ↗
13. 10.3389/fimmu.2018.0181610.3389/fimmu.2018.01816 ↗
14. 10.1186/s13045-018-0644-y10.1186/s13045-018-0644-y ↗
15. 10.1186/s40425-018-0442-710.1186/s40425-018-0442-7 ↗
16. 10.14740/jocmr375010.14740/jocmr3750 ↗
17. 10.1038/s41571-019-0218-010.1038/s41571-019-0218-0 ↗
18. 10.1038/bjc.2017.43410.1038/bjc.2017.434 ↗
19. 10.1200/EDBK_24083710.1200/EDBK_240837 ↗
20. 10.1016/j.immuni.2018.03.00710.1016/j.immuni.2018.03.007 ↗
21. 10.3389/fimmu.2020.0190610.3389/fimmu.2020.01906 ↗
22. 10.1038/s41590-020-00834-910.1038/s41590-020-00834-9 ↗
23. 10.1016/j.ccell.2020.07.00410.1016/j.ccell.2020.07.004 ↗
24. 10.3390/ma1205077910.3390/ma12050779 ↗
25. 10.1039/D0BM00222D10.1039/D0BM00222D ↗
26. Dos Santos A. F. · J. Cancer Metastasis Treat. · 2019 · 5 · 10.20517
27. 10.1111/phpp.1248910.1111/phpp.12489 ↗
28. 10.1021/acsnano.8b0704510.1021/acsnano.8b07045 ↗
29. 10.1186/s40425-019-0826-310.1186/s40425-019-0826-3 ↗
30. 10.1039/C9CC08447A10.1039/C9CC08447A ↗
31. 10.1039/C9TB00630C10.1039/C9TB00630C ↗
32. 10.7150/thno.4607610.7150/thno.46076 ↗
33. 10.1016/j.cej.2019.12207910.1016/j.cej.2019.122079 ↗
34. 10.1021/acsami.8b2257910.1021/acsami.8b22579 ↗
35. 10.1371/journal.pone.006907310.1371/journal.pone.0069073 ↗
36. 10.2217/fon-2020-072010.2217/fon-2020-0720 ↗
37. 10.1016/j.jconrel.2019.05.03610.1016/j.jconrel.2019.05.036 ↗
38. 10.1038/ncomms1319310.1038/ncomms13193 ↗
39. 10.1021/acsnano.7b0071510.1021/acsnano.7b00715 ↗
40. 10.1016/j.biomaterials.2019.11962910.1016/j.biomaterials.2019.119629 ↗
41. 10.1002/adhm.20170007310.1002/adhm.201700073 ↗
42. 10.1016/j.jconrel.2020.03.04510.1016/j.jconrel.2020.03.045 ↗
43. 10.3390/cancers1112185510.3390/cancers11121855 ↗
44. 10.1186/s40580-019-0193-210.1186/s40580-019-0193-2 ↗
45. 10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
46. 10.1002/adhm.20190122310.1002/adhm.201901223 ↗
47. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
48. 10.1038/nnano.2015.34210.1038/nnano.2015.342 ↗
49. 10.1021/nn500211210.1021/nn5002112 ↗
50. 10.1038/s41392-019-0062-910.1038/s41392-019-0062-9 ↗
51. 10.1039/C9TB02238D10.1039/C9TB02238D ↗
52. 10.1016/j.jphotochemrev.2012.09.00410.1016/j.jphotochemrev.2012.09.004 ↗
53. Yang Z. · Mol. Med. Rep. · 2019 · 20 · 5
54. 10.1002/adhm.20190166510.1002/adhm.201901665 ↗
55. 10.1039/D0TB02378G10.1039/D0TB02378G ↗
56. 10.1016/j.ijpharm.2020.11934610.1016/j.ijpharm.2020.119346 ↗
57. 10.1021/acsami.8b1875110.1021/acsami.8b18751 ↗
58. 10.1016/j.jconrel.2019.01.02710.1016/j.jconrel.2019.01.027 ↗
59. 10.1002/adma.20190092710.1002/adma.201900927 ↗
60. 10.3389/fimmu.2013.0043810.3389/fimmu.2013.00438 ↗
61. 10.1021/acs.biomac.8b0046010.1021/acs.biomac.8b00460 ↗
62. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
63. 10.1038/nrc338010.1038/nrc3380 ↗
64. 10.1158/1078-0432.CCR-18-112610.1158/1078-0432.CCR-18-1126 ↗
65. 10.3389/fonc.2019.0119610.3389/fonc.2019.01196 ↗
66. 10.1002/advs.20180215710.1002/advs.201802157 ↗
67. 10.18632/oncotarget.597510.18632/oncotarget.5975 ↗
68. 10.1111/jcmm.1435610.1111/jcmm.14356 ↗
69. 10.1021/acsami.9b0354110.1021/acsami.9b03541 ↗
70. 10.1016/j.biomaterials.2018.05.05110.1016/j.biomaterials.2018.05.051 ↗
71. 10.1016/j.radonc.2008.05.01510.1016/j.radonc.2008.05.015 ↗
72. 10.1002/adtp.20200019110.1002/adtp.202000191 ↗
73. 10.1038/s41427-018-0091-910.1038/s41427-018-0091-9 ↗
74. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
75. 10.1021/acs.bioconjchem.8b0006810.1021/acs.bioconjchem.8b00068 ↗
76. 10.1021/acsnano.0c0561710.1021/acsnano.0c05617 ↗
77. 10.1016/j.canlet.2020.05.01110.1016/j.canlet.2020.05.011 ↗
78. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
79. Ke X. · Oncol. Lett. · 2019 · 18 · 5871
80. 10.1155/2016/205364610.1155/2016/2053646 ↗
81. 10.1016/j.apsb.2017.09.00510.1016/j.apsb.2017.09.005 ↗
82. 10.1016/j.jphotobiol.2020.11191310.1016/j.jphotobiol.2020.111913 ↗
83. 10.3322/caac.2011410.3322/caac.20114 ↗
84. 10.1038/nrc189410.1038/nrc1894 ↗
85. 10.1002/jcp.2949110.1002/jcp.29491 ↗
86. 10.1155/2018/462547210.1155/2018/4625472 ↗
87. 10.1186/s40425-015-0063-310.1186/s40425-015-0063-3 ↗
88. 10.1016/j.bbamcr.2014.05.01410.1016/j.bbamcr.2014.05.014 ↗
89. 10.1021/acsabm.8b0071810.1021/acsabm.8b00718 ↗
90. 10.1039/C8NR05323E10.1039/C8NR05323E ↗
91. 10.1021/acsnano.8b0020410.1021/acsnano.8b00204 ↗
92. 10.1016/j.biomaterials.2019.11937010.1016/j.biomaterials.2019.119370 ↗
93. 10.1021/acsami.8b0587610.1021/acsami.8b05876 ↗
94. 10.1039/C9NR09402D10.1039/C9NR09402D ↗
95. 10.1039/C9TB00089E10.1039/C9TB00089E ↗
96. 10.1016/j.tranon.2020.10082310.1016/j.tranon.2020.100823 ↗
97. 10.1186/s12943-019-1091-210.1186/s12943-019-1091-2 ↗
98. 10.1016/j.it.2018.10.00910.1016/j.it.2018.10.009 ↗
99. 10.1146/annurev-cancerbio-030419-03363510.1146/annurev-cancerbio-030419-033635 ↗
100. 10.4137/IJTR.S3835510.4137/IJTR.S38355 ↗